by Plus Therapeutics | Feb 27, 2026 | Uncategorized
Radiation therapy has been a cornerstone of cancer treatment for more than a century. Its ability to damage cancer cells and control tumor growth has made it one of the most widely used and effective therapeutic modalities in oncology. Yet despite its long history and...
by Plus Therapeutics | Feb 19, 2026 | Uncategorized
As radioligand therapies (RLTs) and theranostics continue to gain momentum across biopharma, the industry is entering a new era—one marked by tremendous opportunity, along with unique regulatory, manufacturing, and reimbursement challenges. In a recent article for...
by Plus Therapeutics | Feb 9, 2026 | Uncategorized
Pharma’s Almanac recently asked a group of biopharma leaders an important question: What emerging technologies or scientific breakthroughs will most reshape biopharma over the next decade? Among those featured was Marc Hedrick, MD, President and CEO of Plus...
by Plus Therapeutics | Feb 4, 2026 | Uncategorized
On World Cancer Day, Plus Therapeutics proudly joins the global oncology community to raise awareness of cancer and reaffirm a shared commitment to improving access to high‑quality, equitable care for patients worldwide. Established in 2000 by the Union for...
by Plus Therapeutics | Jan 29, 2026 | Uncategorized
Marc Hedrick, President & CEO of Plus Therapeutics, recently joined Karen Jagoda on the Empowered Patient Podcast for an in‑depth discussion on the company’s mission to advance care for patients with central nervous system (CNS) cancers. During the interview, Dr....
by Plus Therapeutics | Jan 20, 2026 | Uncategorized
Plus Therapeutics and CNSide Diagnostics are pleased to participate in the Inaugural Brain & Spine Metastases Conference, taking place this Thursday in Miami, Florida. The event brings together leading clinicians, researchers, and innovators focused on advancing...
Recent Comments